The potential energy restriction mimetic agent Delta2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2014

The potential energy restriction mimetic agent Delta2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells

Xiao Yao
  • Fonction : Auteur
Audrey Berthe
  • Fonction : Auteur
  • PersonId : 1203156
Sarra Chbicheb
  • Fonction : Auteur
  • PersonId : 767195
  • IdRef : 154486841
Sandra Kuntz

Résumé

The anticancer effects of thiazolidinediones appear to be independent of their PPAR gamma agonist activity but the molecular mechanisms involved in the anticancer action are not well understood. Results obtained on Ciglitazone derivatives, mainly in prostate cancer cells, suggest that these compounds could act as energy restriction mimetic agents. Our team study the effects of delta 2 troglitazone, a thiazolidinedione devoid of PPAR gamma agonist activity, on breast cancer cell lines. The aim of this work was to better characterize the effects of this compound in terms of apoptosis, ER stress and energy restriction, three events that are observed in response to CGZ derivatives. Our studies performed on two breast cancer cell lines MDA-MB-231 (hormone-independent) and MCF7 (hormone-dependent) show that delta 2-troglitazone triggers ER stress prior to apoptosis but that the two events occur independently. Preliminary results also indicate that the AMP-dependent kinase is activated early. We have now to determine if this is the result of an energy restriction mimetic action.
Fichier non déposé

Dates et versions

hal-01094413 , version 1 (12-12-2014)

Identifiants

  • HAL Id : hal-01094413 , version 1

Citer

Christelle Colin-Cassin, Xiao Yao, Claudia Cerella, Audrey Berthe, Sarra Chbicheb, et al.. The potential energy restriction mimetic agent Delta2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells. Metabolism 2014.
 Alterations of metabolic pathways as therapeutic targets, Jan 2014, Esch-sur Alzette, Luxembourg. ⟨hal-01094413⟩
105 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More